Supplement warning letter
This article was originally published in The Tan Sheet
Executive Summary
Supplements such as Viusid, Kalsis and Oncoxin marketed by Birmingham, Ala.-based Beck Network are unapproved new drugs because of claims Kalsis "can halt and even reverse bone loss" and that Oncoxin contains "anti-cancerous agents with proven efficacy in cancer treatments," a July 19 warning letter to the firm states. FDA cited a total of eight products marketed by the firm and also took issue with the claim "clinical studies have proven Viusid is highly effective for treating HIV/AIDS." The firm must respond to the letter within 15 days of receipt...